Liquidia Corp
Liquidia (LQDA) reported Q2 2026 results with revenue of $171.68 million versus $8.84 million a year earlier, and it swung from a net loss to net income of $74.72 million. For H1 2026, net income rose to $127.58 million from a $79.95 million loss. The article discusses how this profitability shift affects its YUTREPIA and L606 outlook.
Liquidia’s Q2 2026 earnings call said YUTREPIA net sales rose 31% sequentially to $170.4 million, with four quarters of improving profitability. Management attributed adoption to a tolerability-first approach and said YUTREPIA has about 30% share of the inhaled market. It reiterated confidence in >$1 billion net revenue by 2027 and plans higher H2 2026 R&D for trials.
Liquidia (LQDA) fell sharply after reporting Q2 results. The company said revenue rose to about $171.7M versus $8.8M a year earlier, driven mainly by higher sales volume of its commercial drug Yutrepia. Liquidia reported GAAP net income of $74.7M, or $0.74 per share, slightly below the $0.76 consensus. Shares were down about 20% week to date.
Over the past 7 days, alphai's AI scored 6 news stories mentioning LQDA (Liquidia Corp). Coverage has skewed bullish: 4 bullish, 1 neutral, and 1 bearish.
Recent LQDA coverage spans earnings, financial news and insider activity.
In the last 30 days, LQDA insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($24.3M). The most active reporter was Bloch Stephen M with 8 filings. 20% of those filings were made under pre-arranged Rule 10b5-1 plans.
The reported profitability swing and revenue surge are the core catalyst for the stock’s sharp drop, implying investors are reassessing durability of the earnings narrative.
The call provides concrete commercial traction and forward R&D spend plans, which can re-rate near-term growth expectations and trial execution risk.
Earnings beat on revenue and a GAAP profit flip were not enough to offset expectations after a large YTD run, driving a steep sell-off.
Strong Yutrepia commercialization is translating into major top-line growth and profitability, but the post-earnings drop signals valuation or forward-spend concerns.
Commercial traction in YUTREPIA is translating into profitability and cash growth, while R&D spend rises for L606.
alphai scores every news story that mentions LQDA with an AI model for sentiment and relevance, and aggregates insider trades from Liquidia Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Liquidia (LQDA) reported Q2 2026 results with revenue of $171.68 million versus $8.84 million a year earlier, and it swung from a net loss to net income of $74.72 million. For H1 2026, net income rose to $127.58 million from a $79.95 million loss. The article discusses how this profitability shift affects its YUTREPIA and L606 outlook.
7 min readLiquidia’s Q2 2026 earnings call said YUTREPIA net sales rose 31% sequentially to $170.4 million, with four quarters of improving profitability. Management attributed adoption to a tolerability-first approach and said YUTREPIA has about 30% share of the inhaled market. It reiterated confidence in >$1 billion net revenue by 2027 and plans higher H2 2026 R&D for trials.
6 min readLiquidia (LQDA) fell sharply after reporting Q2 results. The company said revenue rose to about $171.7M versus $8.8M a year earlier, driven mainly by higher sales volume of its commercial drug Yutrepia. Liquidia reported GAAP net income of $74.7M, or $0.74 per share, slightly below the $0.76 consensus. Shares were down about 20% week to date.
3 min readLiquidia (LQDA) reported Q2 2026 EPS of 74 cents, above the Zacks estimate of 70 cents. Revenues rose to $171.7 million from $8.8 million a year earlier, beating the $165 million consensus, driven by Yutrepia net product sales of $170.4 million. Shares fell about 10% after results. Liquidia said it targets over $1 billion net revenues in 2027.
7 min readLiquidia Corp (LQDA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622888d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Liquidia Corporation Reports Second Quarter 2026 Financial Results · YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarte
6 min readLiquidia Technologies shares rose 2.7% pre-open ahead of its Q2 2026 results, due Aug. 12, with a webcast at 8:30 a.m. ET. Consensus calls for about $165M revenue and 70 cents EPS. The article cites YUTREPIA commercial traction, with 4,500+ prescriptions and 3,750+ starts as of Apr. 30, 2026, plus recent analyst price-target increases.
4 min readBuckley Capital Advisors’ Q2 2026 investor letter highlights Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical focused on rare cardiopulmonary diseases. It notes LQDA closed July 27, 2026 at $84.42, with a $7.50B market cap. Buckley says it is awaiting Judge Andrews’ decision on whether Liquidia can sell Yutrepia for PH-ILD and expects potential buyout upside.
4 min readBiotech stocks hit 52-week highs on July 24, 2026, including Inhibikase Therapeutics (IKT) at $2.53 after FDA orphan drug designation for IKT-001 and Phase 3 IMPROVE-PAH progress. Jazz Pharmaceuticals (JAZZ) reached $256.75, with Q1 2026 revenue up 19% to $1.1B. Halozyme (HALO) hit $82.99, Q1 revenue $376M (+42%). Corcept (CORT) rose to $97.63, Q1 revenue $164M. Liquidia (LQDA) reached $91.10 on YUTREPIA revenue and net income.
4 min readBloch Stephen M sold 200,000 indirectly-held shares of Liquidia Corp (LQDA) at an average of $88.93 ($87.70–$90.71, $17.79M total) across 5 trades over 2026-07-22 to 2026-07-23.
2 min readBloch Stephen M sold 78,596 indirectly-held shares of Liquidia Corp (LQDA) at an average of $79.97 ($79.55–$80.66, $6.29M total) across 3 trades over 2026-07-20 to 2026-07-21.
2 min read
